<DOC>
	<DOCNO>NCT00002366</DOCNO>
	<brief_summary>To evaluate safety anti-Kaposi 's sarcoma activity ritonavir .</brief_summary>
	<brief_title>The Safety Effectiveness Ritonavir Treatment HIV-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Patients may receive oral acyclovir may continue prophylactic treatment PCP , fungal infection , MAC toxoplasmosis . Topical treatment intralesional chemotherapy allow lesion use indicator biopsy lesion . Concurrent Treatment : Allowed : Localized radiotherapy allow lesion use indicator biopsy lesion . Patients must : Documentation positive ELISA test HIV confirmatory test . Biopsy proven , cutaneous oropharyngeal Kaposi 's sarcoma . Vital sign , physical examination laboratory assessment exhibit evidence acute illness . Patients must agree report current medication primary investigator obtain prior permission use feasible . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Evidence pulmonary Kaposi 's sarcoma . Positive urine screen recreational drug . Current participation another antiviral research study . Investigator anticipate poor patient compliance protocol . Patient condition , investigator 's opinion , may obscure proper observation safety activity ritonavir . Concurrent Medication : Excluded : Antiretroviral therapy . Protease inhibitor therapy . Antiviral agent ( e.g. , oral ganciclovir Foscarnet ) prophylactic medication AIDS define illness patient remove . Chemotherapy Kaposi 's sarcoma . Treatment medication may interact ritonavir . Concurrent Treatment : Excluded : Radiotherapy Kaposi 's sarcoma . Patients follow prior condition exclude : History psychiatric illness currently medically significant . History pancreatitis . Prior Medication : Excluded : All antiretroviral therapy within 2 week prior start treatment phase study . Systemic chemotherapy interferon within 30 day prior study entry . Previous treatment protease inhibitor . Risk Behavior : Excluded : Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Skin Neoplasms</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
</DOC>